Ovoca Bio Plc Logo

Ovoca Bio Plc

OVXA | IR

Overview

Corporate Details

ISIN(s):
IE0006649010 (+1 more)
LEI:
213800ST2AK5XQ1O5207
Country:
Ireland
Address:
17 PEMBROKE STREET UPPER, D02 AT22 DUBLIN
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Ovoca Bio Plc is a clinical-stage biopharmaceutical company with a primary focus on women's health. The company is dedicated to developing novel treatments for female sexual dysfunction. Its lead product candidate, Orenetide (also known as BP-101), is a synthetic peptide designed for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women and has progressed to late-stage clinical development. Recent corporate activity indicates a potential strategic shift, with the company exploring a reverse takeover involving mining assets.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Ovoca Bio Plc. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-05 08:00
Delisting Announcement
Delisting from Euronext Growth Exchange
English 9.0 KB
2025-03-03 15:00
Board/Management Information
Management Changes
English 8.0 KB
2024-12-18 19:00
Post-Annual General Meeting Information
Result of AGM
English 7.1 KB
2024-11-18 08:00
Pre-Annual General Meeting Information
Notice of AGM
English 7.0 KB
2024-10-11 18:30
Major Shareholding Notification
Holding(s) in Company
English 6.8 KB
2024-10-09 18:45
Transaction in Own Shares
Sale of Treasury Shares
English 6.0 KB
2024-09-25 08:00
Report Publication Announcement
Half-year Report
English 7.6 KB
2024-09-02 15:30
Related Party Transaction
Consultancy Agreement
English 8.7 KB
2024-07-15 08:00
Director's Dealing
Director/PDMR Shareholding
English 27.4 KB
2024-07-15 08:00
Board/Management Information
Directorate Change
English 8.8 KB
2024-06-28 08:00
Report Publication Announcement
Annual Financial Report
English 14.5 KB
2024-06-20 00:00
Annual Report
English 1.2 MB
2024-01-23 08:00
Major Shareholding Notification
Holding(s) in Company
English 7.9 KB
2023-12-01 13:00
Post-Annual General Meeting Information
Result of AGM
English 7.8 KB
2023-11-07 10:15
Pre-Annual General Meeting Information
Notice of AGM
English 8.3 KB

Automate Your Workflow. Get a real-time feed of all Ovoca Bio Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Ovoca Bio Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Adocia Logo
Developing novel drug formulations for metabolic diseases like diabetes and obesity for out-licensing.
France ADOC
Aladdin Healthcare Technologies SE Logo
Develops AI for drug discovery and diagnostics targeting age-related diseases.
Germany NMI
Alligator Bioscience Logo
Develops immuno-oncology antibody drugs for cancer, with a lead candidate for pancreatic cancer.
Sweden ATORX
Alten Logo
Global engineering and IT consulting for digital transformation in industry and telecom sectors.
France ATE
AlzeCure Pharma Logo
Clinical-stage pharma developing drugs for CNS diseases like Alzheimer's and pain.
Sweden ALZCUR
Alzinova AB Logo
Develops immunotherapies and vaccines to treat and prevent Alzheimer's disease.
Sweden ALZ
Amoéba Logo
Develops amoeba-based natural fungicides for agriculture and active ingredients for cosmetics.
France ALMIB
Annexin Pharmaceuticals AB Logo
Clinical-stage biotech developing Annexin A5 protein therapies for ophthalmology and oncology.
Sweden ANNX
Aptahem AB Logo
Develops RNA-based aptamer drugs for acute, life-threatening conditions like sepsis.
Sweden APTA
APTAMER GROUP PLC Logo
Develops custom aptamer-based binders as antibody alternatives for life science applications.
United Kingdom APTA